Unicycive Therapeutics’ (UNCY) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Unicycive Therapeutics (NASDAQ:UNCY) in a research report released on Wednesday morning, Benzinga reports. HC Wainwright currently has a $2.50 price objective on the stock.

Several other equities research analysts have also recently issued reports on UNCY. Benchmark reaffirmed a speculative buy rating and set a $3.00 target price on shares of Unicycive Therapeutics in a research note on Friday, September 6th. Brookline Capital Management upgraded shares of Unicycive Therapeutics to a strong-buy rating in a research report on Tuesday, July 9th. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Unicycive Therapeutics currently has a consensus rating of Buy and an average target price of $5.13.

Unicycive Therapeutics Stock Up 3.1 %

UNCY opened at $0.37 on Wednesday. The company has a market cap of $13.91 million, a PE ratio of -0.31 and a beta of 2.36. Unicycive Therapeutics has a twelve month low of $0.20 and a twelve month high of $1.82. The company has a 50-day moving average price of $0.37 and a 200 day moving average price of $0.69.

Unicycive Therapeutics (NASDAQ:UNCY) last announced its earnings results on Wednesday, August 14th. The company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.08. As a group, sell-side analysts expect that Unicycive Therapeutics will post -0.26 earnings per share for the current year.

Institutional Trading of Unicycive Therapeutics

A hedge fund recently bought a new stake in Unicycive Therapeutics stock. Virtu Financial LLC acquired a new position in shares of Unicycive Therapeutics, Inc. (NASDAQ:UNCY) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 26,082 shares of the company’s stock, valued at approximately $36,000. Virtu Financial LLC owned about 0.07% of Unicycive Therapeutics at the end of the most recent quarter. 40.42% of the stock is currently owned by institutional investors.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.